The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) by Wulffraat, N.M. (Nico) et al.
Vol.:(0123456789) 
Rheumatology International (2018) 38 (Suppl 1):S139–S146 
https://doi.org/10.1007/s00296-018-3971-y
VALIDATION STUDIES
The Dutch version of the Juvenile Arthritis Multidimensional 
Assessment Report (JAMAR)
Nico Wulffraat1 · Sylvia Kamphuis2 · Joost F. Swart1 · Sebastiaan Vastert1 · Pieter Van Dijkhuizen1 · 
Philomine van Pelt2 · Annette van Dijk‑Hummelman2 · Alessandro Consolaro3,4 · Francesca Bovis3 · 
Nicolino Ruperto3 · For the Paediatric Rheumatology International Trials Organisation (PRINTO)
Received: 22 December 2017 / Accepted: 11 January 2018
© The Author(s) 2018. This article is an open access publication
Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure 
that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the 
results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Dutch language. 
The reading comprehension of the questionnaire was tested in ten JIA parents and patients. Each participating centre was 
asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen 
in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase 
explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/ceiling effects, 
internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (convergent and 
discriminant validity). A total of 209 JIA patients (14.3% systemic, 39.7% oligoarticular, 25.8% RF negative polyarthritis, 
20.2% other categories) and 107 healthy children were enrolled in two centres. The JAMAR components discriminated well 
healthy subjects from JIA patients. All JAMAR components revealed good psychometric performances. In conclusion, the 
Dutch version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine 
clinical practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Dutch parent, child/adult version of the 
Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
(JIA). The JAMAR assesses the most relevant parent/patient 
reported outcomes in JIA, including overall well-being, 
functional status, health-related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Dutch language.
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Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from February 2012 
to July 2013. Children were recruited after Ethics Commit-
tee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15 items 
in which the ability of the child to perform each task 
is scored as follows: 0 = without difficulty, 1 = with 
some difficulty, 2 = with much difficulty, 3 = unable to 
do and not applicable if it was not possible to answer 
the question or the patient was unable to perform the 
task due to their young age or to reasons other than 
JIA The total PF score ranges from 0 to 45 and has 
three components: PF-lower limbs (PF-LL); PF-hand 
and wrist (PF-HW) and PF-upper segment (PF-US) 
each scoring from 0 to 15 [7]. Higher scores indicating 
higher degree of disability [8–10].
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11].
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint).
 4. Assessment of morning stiffness (present/absent).
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent).
 6. Rating of the level of disease activity on a 21-circle 
VAS.
 7. Rating of disease status at the time of the visit (cat-
egorical scale).
 8. Rating of disease course from previous visit (categori-
cal scale).
 9. Checklist of the medications the patient is taking (list 
of choices).
 10. Checklist of side effects of medications.
 11. Report of difficulties with medication administration 
(list of items).
 12. Report of school/university/work problems caused by 
the disease (list of items).
 13. Assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (five 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14].
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS.
 15. A question about satisfaction with the outcome of the 
illness (yes/no) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted 
in a similar language (i.e Spanish in South American coun-
tries), only the probe technique was performed. Reading 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of 10 JIA parents 
and 10 patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Likert 
assumption [mean and standard deviation (SD) equivalence]; 
the second Likert assumption or equal items-scale correla-
tions (Pearson r: all items within a scale should contribute 
equally to the total score); third Likert assumption (item 
internal consistency or linearity for which each item of a 
scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intraclass correlation coefficient (reproducibil-
ity of the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR sub-
scales with the six JIA core set variables, with the addition 
of the parent assessment of disease activity and pain by the 
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Spearman’s correlation coefficients (r) [17] and the discri-
minant validity, which assesses whether the JAMAR dis-
criminates between the different JIA categories and healthy 
children [18].
Quantitative data were reported as medians with 1st and 
3rd quartiles and categorical data as absolute frequencies 
and percentages.
The complete Dutch parent and patient versions of the 
JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Dutch JAMAR was fully cross-culturally adapted from 
the standard English version with two forward and two back-
ward translations with a concordance for 112/123 transla-
tions lines (91.1%) for the parent version and 108/120 lines 
(90.0%) for the child version.
In the probe technique analysis, 122/123 (99.2%) lines 
of the parent version of the JAMAR were understood by 
at least 80% of the 10 parents tested (median 100%; range 
50–100%). Lines 114 and 115 were modified according to 
parent’s indications; 118/120 (98.3%) lines of the patient 
version of the JAMAR were understood by at least 80% of 
the children (median 100%; range 20–100%). Lines 55 and 
62 were modified according to patient’s indications.
Demographic and clinical characteristics 
of the subjects
A total of 210 JIA patients and 107 healthy children (total 
of 317 subjects) were enrolled at two paediatric rheumatol-
ogy centres. One JIA patient did not give the consent to use 
his/her data.
In the remaining 209 JIA subjects, the JIA categories 
were 14.3% with systemic arthritis, 39.7% with oligoarthri-
tis, 25.8% with RF negative polyarthritis, 4.3% with RF posi-
tive polyarthritis, 4.3% with psoriatic arthritis, 5.7% with 
enthesitis-related arthritis, and 5.7% with undifferentiated 
arthritis (Table 1).
A total of 280/316 (88.6%) subjects had the parent ver-
sion of the JAMAR completed by a parent (203 from parents 
of JIA patients and 77 from parents of healthy children). The 
JAMAR was completed by 238/280 (85.0%) mothers and 
42/280 (15.0%) fathers. The child version of the JAMAR 
was completed by 187/316 (59.2%) children age 5.7 or older. 
Also patients younger than 7 years old, capable to assess 
their personal condition and able to read and write, were 
asked to fill in the patient version of the questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The fol-
lowing results section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items, since 
data were collected through a web-based system that did not 
allow to skip answers and input null values. The response 
pattern for both PF and HRQoL was positively skewed 
toward normal functional ability and normal HRQoL. All 
response choices were used for the different HRQoL items, 
whereas a reduced number of response choices were used 
for PF items 2, 6, 9, 14 and 15.
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items 
(data not shown). The median number of items marked as 
not applicable was 2% (1–3%) for the PF and 5.5% (4–8%) 
for the HRQoL.
Floor and ceiling effect
The median floor effect was 79.3% (72.4–86.7%) for the 
PF items, 54.7% (41.4–54.7%) for the HRQoL-PhH items, 
and 61.1% (60.1–73.9%) for the HRQoL-PsH items. The 
median ceiling effect was 0.5% (0-1.5%) for the PF items, 
5.9% (5.9–8.4%) for the HRQoL-PhH items, and 2.0% 
(0.5–3.0%) for the HRQoL-PsH items. The median floor 
effect was 36.0% for the pain VAS, 29.1% for the disease 
activity VAS and 27.1% for the well-being VAS. The median 
ceiling effect was 0% for the pain VAS, 0.5% for the disease 
activity VAS and 0% for the well-being VAS.
Equal items–scale correlations (second Likert 
assumption)
Pearson items–scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 87% of the PF 
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Table 1  Descriptive statistics (medians, 1st–3rd quartiles or absolute frequencies and %) for the 209 JIA patients
Systemic 
(N = 30)
Oligoarthri-
tis (N = 83)
RF− pol-
yarthritis 
(N = 54)
RF+ pol-
yarthritis 
(N = 9)
Psoriatic 
arthritis 
(N = 9)
Enthesitis-
related 
arthritis 
(N = 12)
Undif-
ferentiated 
arthritis 
(N = 12)
All JIA 
patients 
(N = 209)
Healthy 
(N = 107)
Female 13 (43.3%) 50 (60.2%) 33 (61.1%) 9 (100%) 6 (66.7%) 1 (8.3%) 6 (50%) 118 
(56.5%)*
61 (57%)
Age at visit 11.3 
(6.2–15.4)
10 (6–13) 11.8 
(7.1–15)
16.3 
(15.1–18)
12.1 
(11–15.1)
13.7 (11.7–
16.4)
9.1 (5.3–
14.8)
11.1 
(6.9–15)#
8.7 (5.5–
13.7)*
Age at onset 5.4 (3–10.6) 3.3 (1.9–5.8) 5.9 (2.2–9.8) 12.1 (11.8–
13.5)
5.8 (3.4–
10.8)
11.4 
(9.8–12.6)
3.7 (2–12.1) 5 (2.2–9.6)#
Disease 
duration
3.2 (1.4–5.4) 4.3 (1.7–8.7) 3.6 (1.4–7.5) 3.4 (2.5–4.8) 5.4 (3.7–7.6) 2.4 
(1.6–3.9)
3.3 
(2.1–4.4)
3.7 (1.7–7.2)
ESR 6 (3–18) 7 (3–13) 7 (4–13) 16 (9–28) 9 (4–15) 11.5 
(3–18.5)
4.5 (2.5–
24.5)
7 (3–15)
MD VAS 
(0–10 cm)
0 (0–2) 0 (0–1) 0 (0–2) 1 (0–3) 0 (0–1) 0 (0–1) 0 (0–2) 0 (0–1)
No. swollen 
joints
0 (0–2) 0 (0–1) 0 (0–1) 2 (1–4) 0 (0–2) 0 (0–1) 0 (0–1) 0 (0–1)*
No. joints 
with pain
0 (0–1) 0 (0–1) 0 (0–1) 2 (0–4) 0 (0–2) 0 (0–0.5) 0 (0–0) 0 (0–1)
No. joints 
with LOM
0 (0–7) 0 (0–1) 0.5 (0–2) 2 (2–3) 0 (0–2) 0 (0–0.5) 0 (0–1) 0 (0–2)*
No. active 
joints
0 (0–2) 0 (0–1) 0 (0–2) 2 (1–4) 0 (0–2) 0 (0–1) 0 (0–1) 0 (0–1)*
Active 
systemic 
features
4 (13.3%) 1 (1.2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 5 (2.4%)*
ANA status 0 (0%) 19 (22.9%) 5 (9.3%) 2 (22.2%) 2 (22.2%) 2 (16.7%) 2 (16.7%) 32 (15.3%)
Uveitis 0 (0%) 19/80 
(23.8%)
2/51 (3.9%) 0 (0%) 4 (44.4%) 1/11 (9.1%) 1/11 (9.1%) 27/201 
(13.4%)
PF total 
score
2 (0–6) 1 (0–4) 3 (1–7.5) 6.5 (1–13) 1 (1–2) 0 (0–1) 1 (0–3) 2 (0–5)* 0 (0–0)#
Pain VAS 0.5 (0–3) 1 (0–3.5) 2 (0.5–5) 3.3 (0–7.5) 1.5 (0–5) 0 (0–2) 1.5 (0–3.8) 1.5 (0–4.5) 0 (0–0)#
Disease 
activity 
VAS
0.5 (0–5) 1.3 (0–3.5) 2.3 (0.5–6) 3.5 (0.5–8) 1.5 (0.5–2) 1.5 (0–5.5) 1 (0–3.5) 1.5 (0–5)
Well-being 
VAS
1 (0–4) 2 (0–4) 2.8 (1–5.8) 3 (0.5–6.8) 2 (1.5–4) 1 (0–4.5) 0.3 (0–2.3) 2 (0–4.5)
HRQoL-
PhH
3 (0–6) 3 (0–5) 3 (1–6) 6.5 (0.5–7.5) 2 (1–4) 0 (0–6) 2 (0–3.5) 3 (0–6) 0 (0–1)#
HRQoL-PsH 0 (0–4) 2 (0–4) 2 (0–4) 0.5 (0–4) 1 (0–2) 1 (0–3) 0 (0–1.5) 1 (0–4) 0 (0–1)#
HRQoL total 
score
5 (0–10) 5 (2–9) 5.5 (2–10.5) 7 (0.5–12) 4 (2–5) 3 (1–8) 2 (0.5–5) 5 (1–9) 0 (0–2)#
Pain/swell. 
in > 1 joint
11/29 
(37.9%)
33/82 
(40.2%)
29/52 
(55.8%)
5/8 (62.5%) 3 (33.3%) 2/11 
(18.2%)
5 (41.7%) 88/203 
(43.3%)
2/77 (2.6%)#
Morning 
stiff-
ness > 15 
minutes
5/29 (17.2%) 21/82 
(25.6%)
19/52 
(36.5%)
4/8 (50%) 2 (22.2%) 3/11 
(27.3%)
4 (33.3%) 58/203 
(28.6%)
0 (0%)#
Subjective 
remission
11/29 
(37.9%)
42/82 
(51.2%)
36/52 
(69.2%)
7/8 (87.5%) 5 (55.6%) 4/11 
(36.4%)
5 (41.7%) 110/203 
(54.2%)
In treatment 22/29 
(75.9%)
59/82 (72%) 47/52 
(90.4%)
8/8 (100%) 7 (77.8%) 7/11 
(63.6%)
8 (66.7%) 158/203 
(77.8%)
Reporting 
side effects
6/22 (27.3%) 29/59 
(49.2%)
29/47 
(61.7%)
4/8 (50%) 6/7 (85.7%) 3/7 (42.9%) 5/8 (62.5%) 82/158 
(51.9%)
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items, with the exception of PF items 11 and 15, and for 90% 
of the HRQoL items, with the exception of item 1.
Items internal consistency (third Likert assumption)
Pearson items–scale correlations were ≥ 0.4 for 93% of items 
of the PF (except for PF item 15) and 100% of items of the 
HRQoL.
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.90 for PF-LL, 0.91 for PF-HW, 0.80 
for PF-US. Cronbach’s alpha was 0.89 for HRQoL–PhH and 
0.79 for HRQoL–PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Test–retest reliability
Reliability was assessed in 10 JIA patients, by re-adminis-
tering both versions (parent and child) of the JAMAR after 
a median of 2 days (1–4 days). The intraclass correlation 
coefficients (ICC) for the PF total score showed a substantial 
reproducibility (ICC 0.71). The ICC for the HRQoL-PhH 
and for the HRQoL-PsH showed an almost perfect reproduc-
ibility (ICC 0.90 and ICC 0.83. respectively).
Convergent validity
The Spearman correlation of the PF total score with 
the JIA core set of outcome variables ranged from 0.5 
to 0.7 (median 0.5). The PF total score best correlation 
was observed with the parent assessment of pain (r = 0.7, 
p < 0.001). For the HRQoL, the median correlation of the 
PhH with the JIA core set of outcome variables ranged 
from 0.5 to 0.8 (median 0.5), whereas for the PsH ranged 
from 0.2 to 0.5 (median 0.4). The PhH showed the best 
correlation with the parent’s assessment of pain (r = 0.8, 
p < 0.001) and the PsH with the parent global assess-
ment of well-being (r = 0.6, p < 0.001). The median cor-
relations between the pain VAS, the well-being VAS, and 
the disease activity VAS and the physician-centered and 
laboratory measures were 0.5 (0.3–0.5), 0.4 (0.3–0.5), 0.5 
(0.3–0.5), respectively.
Discussion
In this study, the Dutch version of the JAMAR was cross-
culturally adapted from the original standard English version 
with two forward and two backward translations. Accord-
ing to the results of the validation analysis, the Dutch par-
ent and patient versions of the JAMAR possess satisfactory 
psychometric properties. The disease-specific components 
of the questionnaire discriminated well between patients 
with JIA and healthy controls. The PF total score proved to 
Data related to the JAMAR refers to the 203 JIA patients and to the 77 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD medical doctor, VAS visual analogue 
scale (score 0–10; 0 = no activity; 10 = maximum activity), LOM limitation of motion, ANA anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL health-related quality of life (total score ranges from 0 to 30), PhH physical health (total score ranges from 0 
to 15), PsH psychosocial health (total score ranges from 0 to 15)
p values refers to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05, **p < 0.001, #p < 0.0001
Table 1  (continued)
Systemic 
(N = 30)
Oligoarthri-
tis (N = 83)
RF− pol-
yarthritis 
(N = 54)
RF+ pol-
yarthritis 
(N = 9)
Psoriatic 
arthritis 
(N = 9)
Enthesitis-
related 
arthritis 
(N = 12)
Undif-
ferentiated 
arthritis 
(N = 12)
All JIA 
patients 
(N = 209)
Healthy 
(N = 107)
Taking 
medication 
regularly
21/22 
(95.5%)
54/59 
(91.5%)
43/47 
(91.5%)
8/8 (100%) 6/7 (85.7%) 5/7 (71.4%) 8/8 (100%) 145/158 
(91.8%)
With 
problems 
attending 
school
2/17 (11.8%) 9/52 (17.3%) 12/29 
(41.4%)
1/5 (20%) 1/5 (20%) 1/6 (16.7%) 1/10 (10%) 27/124 
(21.8%)
0 (0%)**
Satisfied 
with 
disease 
outcome
21/29 
(72.4%)
56/82 
(68.3%)
27/52 
(51.9%)
2/8 (25%) 4 (44.4%) 9/11 
(81.8%)
9 (75%) 128/203 
(63.1%)
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discriminate between the different JIA subtypes with chil-
dren with RF positive polyarthritis having a higher degree of 
disability. The overall level of well-being, pain and quality 
of life was comparable among JIA subtypes.
Psychometric evaluation was good for all domains with 
the exception of PF item 15 (bite a sandwich or an apple) 
showing a lower items internal consistency. However the 
overall internal consistency was good for all the domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters were moderate.
The statistical performances of the child version of the 
JAMAR are very similar, although slightly poorer, to those 
obtained by the parent version, which suggests that children 
are reliable reporters of their disease and health status.
The JAMAR addresses side effects of medication, and 
school attendance, which are different dimensions of daily 
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL health-related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent (N = 203/280) Child (N = 143/187)
Missing values (1st–3rd quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 79.3% 83.9%
 HRQoL-PhH 54.7% 53.1%
 HRQoL-PsH 61.1% 64.3%
 Pain VAS 36.0% 33.6%
 Disease activity VAS 29.1% 33.6%
 Well-being VAS 27.1% 31.5%
Ceiling effect, median
 PF 0.5% 0.0%
 HRQoL-PhH 5.9% 5.6%
 HRQoL-PsH 2.0% 1.4%
 Pain VAS 0.0% 1.4%
 Disease activity VAS 0.5% 0.7%
 Well-being VAS 0.0% 1.4%
Items with equivalent item–scale correlation 87% for PF, 90% for HRQoL 87% for PF, 90% for HRQoL
Items with items–scale correlation ≥ 0.4 93% for PF, 100% for HRQoL 67% for PF, 100% for HRQoL
Cronbach’s alpha
 PF-LL 0.90 0.89
 PF-HW 0.91 0.76
 PF-US 0.80 0.55
 HRQoL-PhH 0.89 0.89
 HRQoL-PsH 0.79 0.80
Items with item–scale correlation lower than the Cronbach’s alpha 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 0.71 0.74
 HRQoL-PhH 0.90 0.53
 HRQoL-PsH 0.83 0.91
Spearman correlation with JIA core set variables, median
 PF 0.5 0.5
 HRQoL-PhH 0.5 0.6
 HRQoL-PsH 0.4 0.4
 Pain VAS 0.5 0.5
 Disease activity VAS 0.4 0.4
 Well-being VAS 0.5 0.4
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life from those assessed by the previously used HRQoL 
tools. This may provide useful information for intervention 
and follow-up in health care.
In conclusion, the Dutch version of the JAMAR was 
found to have satisfactory psychometric properties and it 
is, thus, a reliable and valid tool for the multidimensional 
assessment of children with JIA.
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